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creativecommons.org/licenses/by-nc-nd/Abstract Cancer has increasingly become a chronic condition and the routine collection of
patient-reported outcomes (PROs) like quality of life is widely recommended for clinical prac-
tice. Nonetheless, the successful implementation of PROs is still a major challenge, although
common barriers to and facilitators of their beneficial use are well known. To support health
care professionals and other stakeholders in the implementation of the EORTC PRO mea-
sures, the EORTC Quality of Life Group provides guidance on issues considered important
for their use in daily clinical practice. Herein, we present an outline of the newly developed
“’Manual for the use of EORTC measures in daily clinical practice”, covering the following
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Daily clinical routine;
Guidelinemeasures, timing of assessments, scoring and presentation of results * aspects of a strategic
implementation * electronic data assessment and telemonitoring, and * further use of EORTC
measures and ethical considerations. Next to an extensive overview of currently available liter-
ature, the manual specifically focuses on knowledge about EORTC measures to give evidence-
based recommendations whenever possible and to encourage readers and end-users of
EORTC measures to contribute to further needed high-quality research. The manual will be
accessible on the EORTC Quality of Life Group website’s homepage and will be periodically
updated to take into account any new knowledge due to medical, technical, regulatory and
scientific advances.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The focus of cancer care has shifted from a focus mainly
on survival of patients to how patients experience their
disease over the course of treatment, receive aftercare
and live with cancer as a chronic condition. There is a
growing demand for routine monitoring of patient-
reported outcomes (PROs) like quality of life (QOL)
to complement clinical data with the patient’s perspec-
tive. Although routine QOL assessments are recom-
mended in both the literature [1e5] and evidence-based
national guidelines for cancer care [6e8], they are rarely
incorporated in clinical practice, though common bar-
riers and possible solutions are well known [9e11].
As the EORTC instruments are some of the most
often used PRO measures (PROMs) in oncology with
high acceptability [12e14], we developed an EORTC-
specific manual, to supplement the variety of available
EORTC measures with guidance according to their use
in routine care. Our Manual for the use of EORTC
measures in daily clinical practice (available at http://
groups.eortc.be/qol/) addresses all stakeholders inter-
ested in using EORTC instruments as a tool in routine
patient care, providing general information on PROs
and giving particular information on the EORTC mea-
sures. Corresponding to the classic manuscript style of a
narrative review, the aim was to collect an extensive
body of literature, extracting the most important infor-
mation, evidence-based recommendations and explicitly
referencing all sources of information when cited.
Furthermore, considerations for an appropriate imple-
mentation strategy and issues exceeding routine care
make up a large part, to give a comprehensive picture of
the potential of PRO assessments.
In 2011, the International Society for Quality of Life
Research developed a first version of a User’s Guide for
Implementing Patient-Reported Outcomes Assessment in
Clinical Practice [15], which was also published as a
review article [16] and updated in 2015 [17], to provide
basic information for clinicians who are interested in
collecting any kind of PROs (e.g. patient-reported
adverse events, functioning, health status and QOL) intheir clinical practice. Following short informational
paragraphs at the beginning of each chapter, the guide
provides checklists in note form about needed resources,
advantages, disadvantages and further reading refer-
ences for each aspect dealt with. As the International
Society for Quality of Life Research guide and the
EORTC manual differ noticeably concerning covered
issues and how information is presented, users might
benefit most by combining the two sources.
This article is a synopsis of the newly developed
EORTC manual, which offers a narrative review of
relevant PRO literature of five different areas of interest:
(1) Why EORTC PROMs should be used in routine
clinical practice; (2) practical implications concerning
selection, timing of assessments, scoring and presenta-
tion of data assessed with EORTC measures; (3)
implementation of EORTC measures in daily clinical
practice; (4) electronic data assessment and PRO-
telemonitoring; and (5) further areas of application of
EORTC measures and ethical considerations.2. Why EORTC measures should be used in routine
clinical practice
The presented manual uses the term ’EORTC measures’
as an umbrella for all PROMs developed by the EORTC
Quality of Life Group (QLG):
 Stand-alone questionnaires covering issues important for
all cancer patients (EORTC QLQ-C30 [18], EORTC QLQ-
C15-PAL [19], EORTC IN-PATSAT32 [20])
 Additional disease-specific modules [21].
 EORTC computerised adaptive testing (CAT) measures
[22].
 Single items from the EORTC item library (former item
bank) [23] (to create ad hoc checklists when a specific
module is not available or needs to be extended)
EORTC measures undergo a rigorous development
and validation procedure [24] and have been shown to
be applicable across multiple countries and nationalities
[25e27], as development already assesses cross-cultural
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are available.
Several studies have provided evidence that the reg-
ular use of PROMs, including the EORTC measures,
facilitate and improve communication between patients
and health care professionals [29e32], as clinicians’ ac-
cess to PRO data makes discussion of more intimate
issues more likely [33e35] and increases their awareness
of patients’ functioning and well-being [33,35] without
prolonging consultation time [33,36e39]. Furthermore,
the use of PROMs has the potential to facilitate shared
medical decision-making as patient participation is
enhanced [40], to provide appropriate referral to spe-
cialists [41e44], and to enhance continuity of care [32].
Routine electronic assessment of PRO (ePRO) data
enables their being linked to medical data in the elec-
tronic health records or other medical registries which
support clinicians in both therapy-associated data
interpretation and scientific data processing. Efforts to
systematically include PROMs have increased in recent
years, including in publications and white papers
providing advice and best practices [45e47] and the
project of the International Consortium for Health
Outcomes Measurement, which is developing recom-
mendations of common PRO data sets for different
diseases, including EORTC measures [48e50].3. Practical implications concerning selection, timing of
assessments, scoring and presentation of data assessed
with EORTC measures
Owing to the high-methodological quality and wide
range of EORTC measures, users just need to decide
what kind of data they are interested in (EORTC QLQ-
C30 alone, additional disease-related modules, further
issues like information or satisfaction, or EORTC CAT
measures). Issues like the mode of administration (e.g.
paperepencil, electronic, phone calls) and patient
burden need to be taken into account, as they should
impose the least possible burden on the patients, health
care professionals and clinical workflow without omit-
ting important information.
Limited evidence-based recommendations for the
timing of routine assessments with EORTC measures
are available and are mainly derived from expert opin-
ions [17,51]. In clinical practice, comprehensive knowl-
edge of the disease and specific cancer types, treatment
effects and their interaction [51], or at least elaborate
hypotheses concerning this matter, should guide the
timing of assessments (e.g. in advance decisions, if as-
sessments should be time- or event-driven), as otherwise
important information might be missed or patients’
scores might be misjudged [52]. In addition, a predefined
rationale should guide the frequency of PRO assess-
ments, as the evaluation of applied interventions,
routine monitoring of in- or outpatients and long-termmonitoring require different schedules to gather mean-
ingful data. Few clinical models for determining
assessment time-points and frequency have been devel-
oped [53,54], and further research and individual adap-
tation of schedules are warranted.
For EORTC measures, a scoring manual compre-
hensively illustrating the calculation of outcomes is
available [55]. Scores might be interpreted compared to
previous assessments of the same patient, related to
reference populations (e.g. cancer subgroups, general
population, age or gender groups) or to thresholds for
clinical importance. There is a growing interest in
establishing such thresholds to improve the usefulness of
the EORTC QLQ-C30 in daily clinical practice [56e58],
enabling the differentiation between patients with and
without clinically important QOL changes, fostering its
use as a screening tool and providing a reliable decision
aid guiding patient-clinician communication. The
EORTC QLG currently funds an ongoing cross-cultural
project, developing thresholds for clinical importance
for all scales of the EORTC QLQ-C30.
Available literature on graphical presentation for-
mats for the QLQ-C30 mostly focuses on group-level
data [59] from clinical trials. The results of two recent
studies [60,61] investigating presentation styles for PRO
results from individual patients are not conclusive
enough to make definite recommendations on how PRO
data should be presented in clinical practice. Presum-
ably, health care professionals and patients may differ in
their preferences regarding types of graphical presenta-
tion and the amount of information included.
Specific training and information materials tailored
to patients’ or health care professionals’ needs should be
used to enable them to correctly understand the pre-
sented results of the EORTC measures. Fig. 1 provides
examples of presentation styles used by members of the
EORTC QLG.4. Implementation of EORTC measures in daily clinical
practice
Integration of PRO assessments using EORTC mea-
sures into clinical routine is a complex health care
intervention with multiple interacting components on
different levels of the clinical system, all of which are
sensitive to multiple influences and barriers [62,63].
Based on available recommendations on PRO imple-
mentation into clinical practice [e.g. Refs. [10,17,64e67]
and its own experience, the EORTC QLG proposes
some practical approaches to support successful inte-
gration (please refer to Table 1).5. Electronic data assessment and telemonitoring
Routine ePRO assessment with the EORTC measures
provides real-time results, can reduce time and labour
Fig. 1. Examples of graphical presentation of QLQ-C30 results.
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continuous expenditures (e.g. for printing, though costs
for software support might cancel out these
savings) provides high-data quality and improved care
may be achieved. Paperepencil versions can serve as a
back-up or assessment method for those patients who
would otherwise decline assessment (e.g. older people
[78,79]), as studies report a general equivalence between
paperepencil and computer-based versions of PROMs
[80]. At present, jointly with the EORTC QLG, Mapi
[81] is developing guidelines for graphical presentation
formats of electronic versions of the EORTC measures.
Infrastructural requirements for ePRO comprise both
technical and educational aspects. A comprehensive IT
infrastructure is needed and includes technical devices
for data collection and output (workstations, hand-held
devices, preferably equipped with touchscreens),
appropriate software solutions and network facilities for
data transmission, storage and back-up, technical sup-
port and updates. Furthermore, user skills regarding
computer literacy and open-mindedness towards PRO
assessments are of special importance.There are a variety of systems available which allow
ePRO [82e84], but systems vary remarkably concerning
their features. In choosing software for ePRO of
EORTC measures, it should be carefully checked if it is
flexible enough and able to provide all desired func-
tionalities and possibly any future necessary adoptions.
Since 2009, the EORTC QLG has been supporting the
development of the CHES.EORTC software [85], which
allows ePRO in daily clinical practice, clinical studies
and long-term follow-up via telemonitoring and pro-
vides a data exchange interface for clinical information
systems based on the Health Level Seven standard as
well as an elaborated graphical results presentation of
patient-level data [86]. Using CHES.EORTC within a
patient portal accompanied by educational and self-help
material is possible as well.
Continuous assessment of patients’ health status and
QOL outside the hospital via telemonitoring can add to
patient care. Especially patients undergoing active
outpatient treatment might benefit from telemonitoring,
as side effects and treatment-related symptom burden
might occur outside the hospital [87]. Alert systems
Table 1
Single steps of successful implementation of EORTC measures in daily clinical practice.
Understand current practice before applying strategies
for integration.
Existing patient care pathways, knowledge and attitudes towards EORTC
measures as well as the skills of potential adopters should be assessed and
resources and barriers analysed [68]. A baseline assessment could identify
elements relevant for the adaption of practice change, such as benefits, harms and
costs [69].
Engage all relevant stakeholders in all stages of
implementation.
This should include the introduction of existing national guidelines, providing the
opportunity for health care professionals to discuss current practice [70],
engaging senior clinicians, nurse champions and opinion leaders and assigning a
coordinator throughout the implementation process [16].
Collaborate to define the goals and expectations
for routine assessments with EORTC measures
up front to ensure relevance.
Health care professionals’ active participation in the ongoing integration process
ensures that they regard assessments with EORTC measures to be relevant for
their clinical practice, thereby facilitating uptake of the new intervention into
clinical routine.
Make data actionable. Automatic ‘flagging’ of clinically important scores, providing longitudinal
interpretation of what signifies a clinically important change in EORTC measures
data as well as linking of results with clinical practice guidelines and interventions
[30,65,70] are examples how EORTC measures data can be made available for
health care professionals.
Provide training, coaching and support for health
care professionals as well as patients and
their informal caregivers.
A multifaceted, interactive approach [71e73] is expected to be more effective for
practice change than large-scale, passive education materials [74] and detailed
reports on such specific programs are available [75,76]. At the patient level,
disease, cultural and personal aspects should be considered to reduce response
burden [70].
Evaluate integration process and outcome. Defining outcome as well as process indicators together with health care
professionals will help them reflect on the process of integration, to identify
obstacles and to adapt implementation strategies where necessary [30]. Regular
reviews will determine progress, elicit problems and engage health care
professionals in identifying efficient strategies to overcome barriers [68].
Consider organisational context Although implementation is not recommended concurrent with other major
organisational changes [75], organisational adoption will be necessary to support
sustainability of routine assessment of EORTC measures and their being
embedded in integrated cancer care pathways.
Long-term evaluation of effective integration. Long-term follow-up is necessary to determine if short-term changes persist and
whether surrogate outcomes point towards benefits [63]. Quasi-experimental,
observational studies or service development and evaluation models based on
quality improvement and implementation science methods might be more
informative than randomised controlled trials [77].
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symptoms in real time despite the geographic distance
between the patient and medical services, contact pa-
tients and intervene appropriately [88]. Research can
also benefit from telemonitoring with EORTC measures
as such data can be merged with routine assessments at
the hospital and knowledge of the disease itself and
treatment-related symptoms might be deepened.
Telemonitoring seems to be feasible for a consider-
able percentage of cancer patients [89,90] and patients
show more and more interest in the use of electronic
portals [91], which could provide, next to trustworthy
educational and illustrating material, the possibility to
complete EORTC measures as well. There is some evi-
dence suggesting several benefits of using patient portals
including the feeling of being better prepared for clinical
appointments, development of better coping strategies,
higher satisfaction with treatment choices, and better
adherence to medical advice [92].
Nonetheless, efforts need to be made to include pa-
tients who are less likely to engage with electronic as-
sessments due to unfamiliarity with or missing access to
computer technology, lower interest in electronic healthactivities [93,94], or special needs (but auxiliary tools like
adjustable font sizes, voice output or interactive voice
response, additional input devices, telephone interviews
may overcome this problem). Furthermore, implementa-
tion of telemonitoring needs to include a clear strategy on
how to proceed if patient data indicates problems needing
acute medical attention and how patients are effectively
educated about the complementary nature of EORTC
measures. Patients need to be aware that telemonitoring
and using provided educational material and self-help
advice must not replace or delay their visit to the hospi-
tal or doctor if they are feeling unwell.6. Further areas of application of EORTC measures and
ethical considerations
Routinely collected EORTC measures data can be a
valuable source for comparing outcomes with predefined
benchmarks, evaluation of practices, care pathways,
policies, treatment technologies and disclosing systematic
differences in distribution of health care among patients
[95e97]. PRO data might even be used for certification
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patients’ perceptions and patient empowerment.
Even though quality assurance can be a promising
area for the use of PRO, there is a strong need for
further research, as the interests of different stake-
holders vary widely. So far, there are no standards on
how PRO data have to be collected to consider the needs
of all stakeholders without privileging or disadvantaging
any of the parties involved, although some efforts have
been undertaken to develop recommendations con-
cerning this matter [98].
In the near future, EORTC measures can also be used
for cost-utility analysis, and therefore for comparative
effectiveness research [99]. This has become possible
with a recent project of the EORTC QLG and the in-
ternational MAUCa (Multi-Attribute Utility in Cancer)
group, within which the EORTC QLU-C10D measure
was developed, a utility instrument enabling the esti-
mation of quality adjusted life years using the EORTC
QLQ-C30 data [100]. Such analyses may focus on new
treatment modalities or compare existing options,
setting their monetary costs and QOL benefits and im-
pairments against each other. Value sets have currently
been developed for Australia, Germany, Poland,
France and Italy and valuations in further European
countries are planned.
Regarding ethical issues, it is important to balance the
effort PRO assessments impose on patients with the ex-
pected benefit. Which and how many EORTC measures
are used for data collection needs to be carefully chosen
without underestimating the patients’ ability and will-
ingness to complete EORTC measures because they seem
to be ’too ill’. The systematic exclusion of very ill patients
alters data at a group level and may deprive exactly those
patients who are in special need of particular in-
terventions (e.g. referral to psychosocial services).
Before patients start completing EORTC measures,
they need to be extensively informed about the purpose
of assessments, issues concerning data confidentiality
and security and their rights to withdraw from assess-
ments and request destruction of data. Furthermore,
disclosure needs to address common myths about elec-
tronic health interventions and telemonitoring (e.g. the
fear that such interventions are offered because of dis-
ease progression, that the patient’s own coping skills are
insufficient [101], that there will be loss of personal
contact with health care team).
Privacy is not only an issue if ePRO is conducted
(adequate IT structure to ensure maximum data protec-
tion for collection, transmission and storage) but is also
related to the environment of data assessment, as patients
should be able to complete EORTCmeasures unobserved
on their own in a private area, without any time constrains
and the possibility to get help if necessary.
Protecting the confidentiality of patients’ data might
interfere with the usability of data in clinical routine.Some patients might not want all members of their
clinical team to see their data, because they report sen-
sitive information (e.g. sexual issues) or might fear
negative consequences (e.g. following a report of low
satisfaction with care). It is still a challenge to find
adequate ways for data processing and access levels to
preserve the interests of the parties involved.
7. Conclusion
This article briefly summarises the issues covered by our
newly developedManual for the use of EORTC measures
in daily clinical practice, which aims at fostering the
successful implementation of regular PRO assessments
in routine patient care. The field of PRO assessments is
continuously evolving and issues change regarding their
importance and relevance. Medical, technical and reg-
ulatory advances and new scientific insights need to be
taken into account when recommendations about the
routine use of PROs are given. Consequently, guidelines
like the presented EORTC manual need to be periodi-
cally updated. Possible topics to be included in a future
version of the manual could be a more in-depth dis-
cussion on the use of EORTC measures for continuity of
care, a critical appraisal of the possible use of the
EORTC measures for quality assurance, a summary of
the Mapi/EORTC QLG guidelines on the graphical
presentation of EORTC measures in ePRO software,
and the possible linkage between EORTC measures and
self-management programs. As this manual is made for
end-users of EORTC measures, any comments and
suggestions for improvement and further development
of the manual are warmly welcome: http://groups.eortc.
be/qol/contact-us.
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